ATE344668T1 - Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus - Google Patents

Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus

Info

Publication number
ATE344668T1
ATE344668T1 AT97923573T AT97923573T ATE344668T1 AT E344668 T1 ATE344668 T1 AT E344668T1 AT 97923573 T AT97923573 T AT 97923573T AT 97923573 T AT97923573 T AT 97923573T AT E344668 T1 ATE344668 T1 AT E344668T1
Authority
AT
Austria
Prior art keywords
agonist
glucose metabolism
fat
composition
adrenergic
Prior art date
Application number
AT97923573T
Other languages
English (en)
Inventor
Anthony H Cincotta
Original Assignee
Pliva Istrazivanje I Razvoj D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Istrazivanje I Razvoj D filed Critical Pliva Istrazivanje I Razvoj D
Application granted granted Critical
Publication of ATE344668T1 publication Critical patent/ATE344668T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT97923573T 1996-05-07 1997-05-06 Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus ATE344668T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1737796P 1996-05-07 1996-05-07
US1933696P 1996-06-06 1996-06-06

Publications (1)

Publication Number Publication Date
ATE344668T1 true ATE344668T1 (de) 2006-11-15

Family

ID=26689794

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97923573T ATE344668T1 (de) 1996-05-07 1997-05-06 Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus

Country Status (8)

Country Link
EP (2) EP1776955B1 (de)
AT (1) ATE344668T1 (de)
CA (1) CA2254116C (de)
DE (1) DE69736928T2 (de)
DK (1) DK0934069T3 (de)
ES (2) ES2393303T3 (de)
PT (1) PT934069E (de)
WO (1) WO1997041873A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6366298B1 (en) 1999-06-03 2002-04-02 Netzero, Inc. Monitoring of individual internet usage
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040077679A1 (en) * 2002-07-29 2004-04-22 Cincotta Anthony H. Therapeutic treatment for the metabolic syndrome and type 2 diabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
HUE034290T2 (en) 2003-04-29 2018-02-28 Orexigen Therapeutics Inc Preparations containing opioid antagonist and bupropion to affect weight loss
EP1870096A3 (de) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Zusammensetzungen zur Beeinflussung von Gewichtsverlust
CA2630624C (en) 2005-11-22 2013-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
AU2013263800B2 (en) * 2007-03-30 2016-05-05 Veroscience Llc Methods of treating metabolic syndrome using dopamine receptor agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
EP2217067A4 (de) * 2007-11-07 2011-01-19 Burnham Inst Medical Research Verfahren und verbindungen zur modulation der insulinproduktion
AU2015201255B2 (en) * 2008-01-14 2016-05-19 Veroscience, Llc Parenteral formulations of dopamine agonists
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
LT3730132T (lt) 2012-06-06 2022-08-25 Nalpropion Pharmaceuticals Llc Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US20210330616A1 (en) * 2018-09-03 2021-10-28 Metabolic And Obese Research Science Corporation Ameliorating agent for obesity-related metabolic disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012793A1 (en) * 1991-12-23 1993-07-08 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College A therapeutic process for the treatment of the pathologies of type ii diabetes

Also Published As

Publication number Publication date
EP0934069A4 (de) 2002-12-04
HK1108312A1 (en) 2008-05-02
ES2393303T3 (es) 2012-12-20
WO1997041873A1 (en) 1997-11-13
DE69736928T2 (de) 2007-06-28
DE69736928D1 (de) 2006-12-21
ES2277357T3 (es) 2007-07-01
PT934069E (pt) 2007-02-28
CA2254116C (en) 2009-10-20
EP1776955B1 (de) 2012-08-15
EP1776955A1 (de) 2007-04-25
DK0934069T3 (da) 2007-03-19
EP0934069B1 (de) 2006-11-08
CA2254116A1 (en) 1997-11-13
EP0934069A1 (de) 1999-08-11

Similar Documents

Publication Publication Date Title
ATE344668T1 (de) Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus
ATE207352T1 (de) Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
DE69535498D1 (de) Verfahren zur behandlung vaskulärer kopfschmerzen
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69733611D1 (de) Verfahren und potenzierte zusammensetzung zur behandlung von migräne
DE69527847D1 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
DE69611251D1 (de) Hydroperoxeicosatetraensäure derivate enthaltende zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
DE69400824D1 (de) Indol-derivate als 5-ht1-ähnliche antagonisten zur behandlung von migräne
ATE298566T1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
ES2184111T3 (es) Composiciones para el tratamiento de neuropatias perifericas que contienen antidepresivos y/o inhibidores de la monoaminoxidasa y/o vitamina b12 y/o precursores o inductores de un neurotransmisor.
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
DE69332713D1 (de) Verwendung von Histamine-2 Agonisten zur Behandlung sexueller Funktionsstörungen
ATE218330T1 (de) Verwendung von transglutaminasehemmer zur behandlung des narbegewebes
EP1098642A4 (de) Verfahren zur behandlung von zustanden moduliert durch lactosylceramiden
BG101937A (en) Pharmaceutical compositions comprising monoamine oxidase b inhibitors
DE69535319D1 (de) Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten
ATE78162T1 (de) 5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion.
ATE203162T1 (de) Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4- aza-5 alpha-androst-1-en-3-one
ATE37141T1 (de) Haarkurmittel und verfahren zur haarbehandlung.
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
DE69623767D1 (de) Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus
ATE438859T1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
DE60017793D1 (de) Verfahren zur vorbeugung und behandlung von beschädigung des schleimhautgewebes
ATE432359T1 (de) Modulation der s6-kinaseaktivität zur behandlung von adipositas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0934069

Country of ref document: EP

EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee